Skip to main content
. 2016 Feb 26;6:22120. doi: 10.1038/srep22120

Figure 5. A drug combination inhibits cell proliferation more effectively in lung adenocarcinoma cell lines with a BRAF mutation and PIM1 upregulation.

Figure 5

Cell growth inhibition assays for NCI-H2087 (A) and NCI-H1395 (B) cell lines. Cells were treated with increasing concentrations of SB590885, LY294002, or a combination of SB590885 and LY294002 for 72 h, and cell viability was determined by cell counting using a hemocytometer. Error bars show standard error for the data, and means were derived from two replicates (n = 2). NCI-H2087 (C) and NCI-H1395 (D) cell lines were transfected with PIM1 siRNA. After six hours, the cell culture media was replaced, SB590885 (0.05 uM) was added to the media, and the cells were cultured for 66 h before they were harvested and counted. Error bars show standard error for the data, and means were derived from two replicates (n = 2).